From BILAG to BILAG-based combined lupus assessment-30 years on

被引:18
作者
Murphy, Claire-Louise [1 ]
Yee, Chee-Seng [2 ]
Gordon, Caroline [3 ]
Isenberg, David [1 ]
机构
[1] UCL, Ctr Rheumatol, London, England
[2] Doncaster & Bassetlaw Hosp NHS Fdn Trust, Dept Rheumatol, Doncaster Royal Infirm, Doncaster, England
[3] Univ Birmingham, Rheumatol Res Grp East Wing, Sch Immun & Infect, Coll Med & Dent Sci, Birmingham, W Midlands, England
关键词
SLE; lupus; lupus activity; BILAG; disease activity indices; clinical trials; autoimmunity; rheumatology; measurement; scoring; BILAG-2004; DISEASE-ACTIVITY INDEX; B-CELL DEPLETION; CLINICAL-TRIALS; ERYTHEMATOSUS; SLE; VALIDATION; RITUXIMAB; RELIABILITY; INSTRUMENT; COLLEGE;
D O I
10.1093/rheumatology/kev387
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Disease activity in SLE can be difficult to measure and there is no biomarker that uniformly reflects disease activity. There are various disease activity scores, but there is no gold standard assessment tool. This is a review of the development of the BILAG index from the classic BILAG disease activity index to the BILAG-2004 disease activity index and composite response criteria. The original classic BILAG index was revised and distinguished nine organs/systems. Features that indicated damage, such as avascular necrosis, were excluded. There was improvement in the glossary, scoring system and software. The BILAG-2004 index has been shown to be reliable, valid and sensitive to change. The BILAG-2004 index has been modified for pregnancy and has also been used in paediatrics. The SLE Responder Index (SRI) and the BILAG-based combined lupus assessment (BICLA) are composite responder indices incorporating the BILAG index. Since the initial development of the BILAG index in 1984, major improvements have been made in the measurement of disease activity in lupus. However, the BILAG-2004 index is the only transitional index that grades clinical features as being new, the same, worse or improving and incorporates severity in the scoring.
引用
收藏
页码:1357 / 1363
页数:7
相关论文
共 38 条
  • [1] DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS
    BOMBARDIER, C
    GLADMAN, DD
    UROWITZ, MB
    CARON, D
    CHANG, CH
    [J]. ARTHRITIS AND RHEUMATISM, 1992, 35 (06): : 630 - 640
  • [2] Numerical scoring for the Classic BILAG index
    Cresswell, Lynne
    Yee, Chee-Seng
    Farewell, Vernon
    Rahman, Anisur
    Teh, Lee-Suan
    Griffiths, Bridget
    Bruce, Ian N.
    Ahmad, Yasmeen
    Prabu, Athiveeraramapandian
    Akil, Mohammed
    McHugh, Neil
    Toescu, Veronica
    D'Cruz, David
    Khamashta, Munther A.
    Maddison, Peter
    Isenberg, David A.
    Gordon, Caroline
    [J]. RHEUMATOLOGY, 2009, 48 (12) : 1548 - 1552
  • [3] A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
    Furie, Richard
    Petri, Michelle
    Zamani, Omid
    Cervera, Ricard
    Wallace, Daniel J.
    Tegzova, Dana
    Sanchez-Guerrero, Jorge
    Schwarting, Andreas
    Merrill, Joan T.
    Chatham, W. Winn
    Stohl, William
    Ginzler, Ellen M.
    Hough, Douglas R.
    Zhong, Z. John
    Freimuth, William
    van Vollenhoven, Ronald F.
    [J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (12): : 3918 - 3930
  • [4] GLADMAN DD, 1992, J RHEUMATOL, V19, P608
  • [5] Definition and treatment of lupus flares measured by the BILAG index
    Gordon, C
    Sutcliffe, N
    Skan, J
    Stoll, T
    Isenberg, DA
    [J]. RHEUMATOLOGY, 2003, 42 (11) : 1372 - 1379
  • [6] The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE
    Griffiths, Bridget
    Emery, Paul
    Ryan, Vicky
    Isenberg, David
    Akil, Mohammed
    Thompson, Robert
    Maddison, Peter
    Griffiths, Ian D.
    Lorenzi, Alice
    Miles, Sarah
    Situnayake, Deva
    Teh, Lee Suan
    Plant, Mike
    Hallengren, Christina
    Nived, Ola
    Sturfelt, Gunnar
    Chakravarty, Kuntal
    Tait, Tim
    Gordon, Caroline
    [J]. RHEUMATOLOGY, 2010, 49 (04) : 723 - 732
  • [7] HAY EM, 1993, Q J MED, V86, P447
  • [8] The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus
    Hickman, R. A.
    Hira-Kazal, R.
    Yee, C. -S.
    Toescu, V.
    Gordon, Caroline
    [J]. CLINICAL RHEUMATOLOGY, 2015, 34 (02) : 263 - 271
  • [9] The Systemic Lupus International Collaborating Clinics (SLICC) group - It was 20 years ago today
    Isenberg, D. A.
    Ramsey-Goldman, R.
    Gladman, D.
    Hanly, J. G.
    [J]. LUPUS, 2011, 20 (13) : 1426 - 1432
  • [10] An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA
    Isenberg, D. A.
    Allen, E.
    Farewell, V.
    D'Cruz, D.
    Alarcon, G. S.
    Aranow, C.
    Bruce, I. N.
    Dooley, M. A.
    Fortin, P. R.
    Ginzler, E. M.
    Gladman, D. D.
    Hanly, J. G.
    Inanc, M.
    Kalunian, K.
    Khamashta, M.
    Merrill, J. T.
    Nived, O.
    Petri, M.
    Ramsey-Goldman, R.
    Sturfelt, G.
    Urowitz, M.
    Wallace, D. J.
    Gordon, C.
    Rahman, A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (01) : 54 - 59